- Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
- Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
- Athira Pharma to Participate in Upcoming June Conferences
- Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
- Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
- Athira Pharma to Participate in Upcoming May Conferences
- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
- Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
- Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
More ▼
Key statistics
On Wednesday, Athira Pharma Inc (ATHA:NSQ) closed at 2.57, 93.23% above the 52 week low of 1.33 set on Nov 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.52 |
---|---|
High | 2.65 |
Low | 2.48 |
Bid | 2.47 |
Offer | 2.61 |
Previous close | 2.52 |
Average volume | 96.66k |
---|---|
Shares outstanding | 38.33m |
Free float | 31.91m |
P/E (TTM) | -- |
Market cap | 98.50m USD |
EPS (TTM) | -3.05 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼